26.78 USD
-0.13 (-0.48%)
26.87 USD
+0.09 (+0.34%)
We assign a fundamental rating of 5 out of 10 to ACAD. ACAD was compared to 530 industry peers in the Biotechnology industry. ACAD has an excellent financial health rating, but there are some minor concerns on its profitability. ACAD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD always reported negative net income.
ACAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.63%, ACAD belongs to the top of the industry, outperforming 96.98% of the companies in the same industry.
ACAD's Return On Equity of 28.47% is amongst the best of the industry. ACAD outperforms 97.55% of its industry peers.
With an excellent Return On Invested Capital value of 7.66%, ACAD belongs to the best of the industry, outperforming 93.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD has a better Profit Margin (24.94%) than 94.91% of its industry peers.
The Operating Margin of ACAD (9.02%) is better than 91.13% of its industry peers.
With an excellent Gross Margin value of 91.92%, ACAD belongs to the best of the industry, outperforming 93.21% of the companies in the same industry.
ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 6.08 indicates that ACAD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.08, ACAD is in the better half of the industry, outperforming 74.15% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.08 |
ROIC/WACC0.87
WACC8.83%
2.3 Liquidity
ACAD has a Current Ratio of 3.02. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.02, ACAD is not doing good in the industry: 63.96% of the companies in the same industry are doing better.
ACAD has a Quick Ratio of 2.94. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a Quick ratio of 2.94. This is in the lower half of the industry: ACAD underperforms 62.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.78% yearly.
Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 10.04% on average per year.
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y38.78%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.04%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 39.97 indicates a quite expensive valuation of ACAD.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.51% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. ACAD is valued slightly more expensive when compared to this.
Based on the Price/Forward Earnings ratio of 33.26, the valuation of ACAD can be described as expensive.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.89% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ACAD to the average of the S&P500 Index (23.88), we can say ACAD is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.97 | ||
| Fwd PE | 33.26 |
4.2 Price Multiples
ACAD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ACAD is cheaper than 92.83% of the companies in the same industry.
95.47% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.81 | ||
| EV/EBITDA | 28.74 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
ACAD's earnings are expected to grow with 35.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y35.28%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
26.78
-0.13 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.21%
Inst Owner Change0%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.53B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target29.96 (11.87%)
Short Float %5.18%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)1.86%
PT rev (3m)1.08%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)5.79%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)43.73%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.97 | ||
| Fwd PE | 33.26 | ||
| P/S | 4.33 | ||
| P/FCF | 20.81 | ||
| P/OCF | 14.26 | ||
| P/B | 4.94 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | 28.74 |
EPS(TTM)0.67
EY2.5%
EPS(NY)0.81
Fwd EY3.01%
FCF(TTM)1.29
FCFY4.81%
OCF(TTM)1.88
OCFY7.01%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.56
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 6.08 |
F-Score4
WACC8.83%
ROIC/WACC0.87
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y38.78%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.04%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the fundamental rating for ACAD stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?
The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 39.97 and the Price/Book (PB) ratio is 4.94.
Can you provide the financial health for ACAD stock?
The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.